Dogwood Therapeutics, Inc.

DWTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.49

+$0.16 · +6.87%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

27/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Expensive

Momentum

Strong Down

Sentiment

Mixed

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Gregory Duncan
Listed since: Dec 17, 2020
Employees: 8

Market position

Day range

Current $2.49

$2.31$2.5757

52-week range

Current $2.49

$1.28$9.50

Open: $2.31
Previous close: $2.33
Volume: 123.42K; 1.35× average
Average volume: 91.4K; Average daily volume
Market cap: 83.74M USD
Beta: 1.76; Market reference 1
50-day average: $1.649; +51.00% above average
200-day average: $2.8681; -13.18% below average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score: 0.89
Piotroski F-score: 1 of 9

Financial statements

Income trends

Operating income

−27.97M USD-128.74%

Net income

−34.26M USD-177.39%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	21.87M USD	3.53M USD	1.73M USD	8.07M USD	10.8M USD
Selling, general, and administrative	6.1M USD	8.7M USD	3.72M USD	4.25M USD	4.85M USD
Operating expenses	27.97M USD	12.23M USD	5.45M USD	12.32M USD	15.64M USD
Interest income	96.94K USD	—	150.9K USD	67.48K USD	5.67K USD
Interest expense	—	92.19K USD	—	—	—
Depreciation and amortization	2.06K USD	12.18K USD	—	—	—
Operating income	−27.97M USD	−12.23M USD	−5.45M USD	−12.32M USD	−15.64M USD
Net income	−34.26M USD	−12.35M USD	−5.3M USD	−12.25M USD	−15.96M USD